Alarming Immunity: A Wake up Call for Cd8 T Cells Using Genetic Adjuvants (il-33 and Isg15)
Degree type
Graduate group
Discipline
Subject
CD8 T cells
Cytokines
Interleukin 33
ISG15
Vaccines
Allergy and Immunology
Immunology and Infectious Disease
Medical Immunology
Molecular Biology
Funder
Grant number
License
Copyright date
Distributor
Related resources
Author
Contributor
Abstract
There exists a paramount need for effective vaccines against cancer, TB, malaria, HIV, HCV, and other chronic infections. The hope for long-term control of these important diseases ultimately may depend upon development of potent T cell-based therapeutic vaccines. However, current, licensed vaccines or capable vaccine platforms have not made a substantial impact on treatment of these conditions, likely due in part to poor CD8 T cell immune induction. Thus, identification of novel adjuvants to be deployed to induce effective T responses is an important area of research in T cell based vaccines. While multiple adjuvants have been readily identified which impact CD4 T cells, it has been a challenging task to identify adjuvants that can amplify CD8 T cell responses. In this regard, Interleukin 33 (IL-33) and Interferon Stimulated Gene 15 (ISG15) have emerged as immunomodulatory molecules facilitating the generation of TH1-mediated T cell immunity; however, their ability to function as vaccine adjuvants to enhance CD8 T cell immunity was not previously explored. Here we used a DNA-vaccination approach to investigate the effect of IL-33 and/or ISG15 on vaccine-induced CD8 T cell immune responses. My studies showed that both IL-33 and ISG15 served as effective vaccine adjuvants to enhance the antigen-specific, polyfunctional, and cytolytic effector CD8 T cell responses in vivo. Importantly, I demonstrate for the first time the efficacy of both IL-33 and ISG15 as DNA vaccine adjuvants in driving viral or tumor protective immunity. Consideration of our findings, combined with a further understanding of the functional roles of these molecular adjuvants in immune expansion, likely will aid in the development of therapies for augmenting T cell based responses against many infectious diseases and cancers.